Predictors of acute kidney injury associated with intravenous colistin treatment

Kwon, Jeong-Ah; Lee, Jung Eun; Huh, Wooseong; Peck, Kyong Ran; Kim, Yoon-Goo; Kim, Dae Joong; Oh, Ha Young

doi:10.1016/j.ijantimicag.2009.12.002

Cited by 104 publications

(107 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma colistin concentration are sometimes suboptimal with recommended dose regimen, 22,23 increasing dose may cause nephrotoxicity. 22,24,25 Colistin activity can be enhanced when combined with antibiotics with different action as carbapenems, rifampicin, ceftazidime. 26,27,28 Present study observd 50% synergism, 30% additive effect, 20% indifference while combining colistin with imipenem.…”

Section: Discussionmentioning

confidence: 99%

In vitro efficacy of synergistic antibiotic combinations in imipenem resistant Pseudomonas aeruginosa strains

Farzana

Shamsuzzaman

2017

Bangladesh J Med Microbiol

View full text Add to dashboard Cite

imipenem resistant isolates ranged from > _ 256 mg/L to < _ 8 mg/L for imipenem, > _ 1024 mg/L to < _ 64 mg/L for ceftriaxone, > _ 256 mg/L to < _ 8 mg/L for amikacin, > _ 16 mg/L to < _ 2 mg/L for colistin, > _ 512 mg/L to < _ 16 mg/L for piperacillin/tazobactam. Among antibiotic combinations, piperacillin/tazobactam-amikacin was most effective with 80% synergism next to which was imipenem-amikacin with 60% synergism, then imipenem-colistin with 50% synergism, imipenem-ceftriaxone with 30% synergism. Only one combination (piperacillin/tazobactum -imipenem showed 20% antagonism. All these combinations had considerable proportion of additive effect which is also desirable for these multi drug resistant isolates

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro efficacy of synergistic antibiotic combinations in imipenem resistant Pseudomonas aeruginosa strains

Farzana

Shamsuzzaman

2017

Bangladesh J Med Microbiol

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7] Recommended empiric antimicrobial regimens for these patients, which include antipseudomonal b-lactams, do not have activity against CRE, and identification of CRE from clinical isolates may take up to 3 d. 8 Further, targeted therapy for CRE infections may be complicated by the use of combination therapy with potentially toxic antimicrobials, including the polymyxins and aminoglycosides, as well as rifampin, which may interact with concomitantly administered immunosuppressive agents and prophylactic agents. [8][9][10] This review summarizes our current understanding of the epidemiology and outcomes of CRE infections in solid organ and stem cell transplant recipients, as well as in patients with hematologic malignancies. We will also discuss CRE treatment and prevention strategies germane to the immunocompromised host.…”

mentioning

confidence: 99%

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

2016

View full text Add to dashboard Cite

Carbapenem-resistant Enterobacteriaceae (CRE) are a major global public health concern and pose a serious threat to immunocompromised hosts, particularly patients with hematologic malignancies and solid organ (SOT) and stem cell transplant recipients. In endemic areas, carbapenem-resistant Klebsiella pneumoniae infections occur in 1-18% of SOT recipients, and patients with hematologic malignancies represent 16-24% of all patients with CRE bacteremia. Mortality rates approaching 60% have been reported in these patient populations. Early diagnosis and rapid initiation of targeted therapy is critical in the management of immunocompromised hosts with CRE infections, as recommended empiric regimens are not active against CRE. Therapeutic options are limited by antibiotic-associated toxicities, interactions with immunosuppressive agents, and paucity of antibiotic options currently available. Prevention of CRE infection in these patients requires a multidisciplinary approach involving hospital epidemiology and antimicrobial stewardship. Large, multicenter studies are needed to develop risk-stratification tools to assist in guiding the management of these individuals.

show abstract

“…In some studies, concomitant NSAID or vancomycin use, hypertension, and older age were identified as independent risk factors for colistin-induced AKI (6,14,24,25), whereas these findings were not corroborated in several other studies, including ours (10,13,17,19,25,26).…”

Section: Discussionmentioning

confidence: 61%

“…The rates of colistin-induced AKI reported in the literature vary between 11z and 53.5z (3,4,6,9,10,(13)(14)(15)(16)(17). This variability could be attributed to the dose and duration of the therapies, and to the varying definitions of AKI.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey

Gül

Kuşçu²,

Aydemir

et al. 2016

Jpn J Infect Dis

View full text Add to dashboard Cite

Predictors of acute kidney injury associated with intravenous colistin treatment

Cited by 104 publications

References 23 publications

In vitro efficacy of synergistic antibiotic combinations in imipenem resistant Pseudomonas aeruginosa strains

In vitro efficacy of synergistic antibiotic combinations in imipenem resistant Pseudomonas aeruginosa strains

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey

Contact Info

Product

Resources

About